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ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM 
PATIENTS WITH COMMUNITY-ACQUIRED RESPIRATORY TRACT 
INFECTIONS IN PAKISTAN—THE ACTIVE STUDY 
Afia Zafar, Zahid Hussain*, Eale Lomama**, Sophie Sibille**, Seema Irfan, Erum Khan 
Department of Pathology and Microbiology, The Aga Khan University, Karachi, Pakistan, *Medical Department, sanofi-aventis, 
Pakistan Limited, **sanofi-aventis France. 
Background: Respiratory tract infections (RTIs) are amongst the most wide spread and serious 
infections, accounting for over 50 million deaths globally each year. In developing countries, infants 
under 4 years of age are at greatest risk of lower RTIs, whereas in developed countries the severity of 
infection and rate of mortality are greater in elderly. The objective of the survey was to determine the in 
vitro susceptibility of antibiotics commonly prescribed RTIs against Streptococcus pneumoniae (SP), 
Haemophilus influenzae (HI) and Streptococcus pyogenes, isolated from patients with community-
acquired RTIs globally. This survey involved 9 countries. In this study we present the results from 
Pakistan where SP and HI only were tested. Methods: A total of 200 isolates were included in the 
study. Both SP and HI were in equal number. Antibiotic susceptibility testing was performed by using 
Clinical and Laboratory Standards Institute guidelines and E test for determination of the minimal 
inhibitory concentration. For non-US products the Committee of the Antibiogram of the French Society 
of Microbiology Breakpoints was used. Results: All SP were found susceptible to amoxicillin, co-
amoxiclave and cefixime, 72% isolates were found sensitive to macrolide and 97% to levofloxacin. All 
HI were found sensitive to co-amoxiclave and to cefixime, 97% to ampicillin, 98% to clarithromycin 
and 99% to levofloxacin. Conclusion: In isolates collected from Pakistan, SP resistance rate was 
elevated for macrolide. SP and HI remain susceptible to β-lactams as well as to levofloxacin.  
Keywords: Community acquired pneumonia, antibiotic susceptibility, respiratory pathogens
INTRODUCTION 
Respiratory tract infections (RTIs) are amongst the most 
wide spread and serious infections, accounting for over 
50 million deaths globally each year. RTIs also are the 
most common reason for physician visits and prescription 
of antibiotics.1,2 Infections of lower respiratory tract 
include community-acquired pneumoniae (CAP) and 
acute exacerbations of chronic bronchitis (AECB), which 
are associated with significant rates of mortality and are 
among the top 10 causes of death in developed world. In 
developing countries, infants under 4 years of age are at 
greatest risk of lower RTIs, whereas in developed 
countries the severity of infection and rate of mortality are 
greater in elderly.3 Antibacterial resistance among the 
pathogens commonly involved in community-acquired 
RTI such as Streptococcus pneumoniae, Haemophilus 
influenzae, has increased over the last decades and may 
jeopardize the effectiveness of the treatment of RTI. 
In Pakistan, most RTIs are treated empirically, 
perhaps due to higher cost of laboratory services or non 
availability of standardized laboratories. Surveillance 
studies are important tool for defining regional patterns 
of antimicrobial resistance, guiding empirical therapy 
and establishment of guidelines. Therefore, this study 
was conducted to determine susceptibility patterns of 
common respiratory tract pathogens seen in community.  
MATERIALS AND METHODS 
This study was conducted in the Clinical 
Microbiology Laboratory of Aga Khan University 
Hospital in 2006. A total of 200 isolates were 
included in the study. Both S. pneumoniae and H. 
influenzae were in equal number. Single isolate from 
each patient with the diagnosis of community-
acquired LRTIs, i.e., pneumonia, AECB, acute 
exacerbation of chronic obstructive airways disease, 
presumed secondary bacterial infection of acute 
bronchitis was included in the study. Clinical isolates 
of upper respiratory infections such as   sinusitis and 
acute otitis media were also included.  
Both pathogens were identified as per standard 
methodology.4 S. pneumoniae was identified on the 
basis of gram stain characteristics, colony morphology, 
catalase test and susceptibility to optochin. For H. 
influenzae gram stain characteristics, colony 
morphology and requirement of XV factors was used. 
Antibiotic susceptibility testing 
Antibiotic susceptibility testing was performed by 
using Kirby Bauer disk diffusion method as per 
Clinical Laboratory Standards Institute (CLSI) 
Guidelines.5 Following antibiotics were included: 
ampicillin (10 µg) amoxicillin (10 µg), co-
amoxiclave (30 µg) cefixime (5 µg) erythromycin (15 
µg) levofloxacin (5 µg), clarithromycin (15 µg). E 
test (Bio Meurex) was used for determination of the 
Minimal Inhibitory Concentration (MIC). The results 
were interpreted according to CLSI guidelines. 
Statistics 
All statistical analyses were conducted on SAS®, 
Release 9.1 (SAS Institute, SAS Campus Drive, Cary 
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NC 27513), and run under Microsoft Windows XP® for 
a personal computer. Electronic data capturing and data 
validation was conducted by sanofi-aventis,     Midrand, 
South Africa. Categorization of test outcomes (as 
susceptible, intermediate or resistant) was done centrally 
by sanofi-aventis, Midrand, South Africa. 
RESULTS 
DEMOGRAPHIC DATA  
The age distribution of patients for S. pneumoniae: 
Twenty-four percent of the patients belonged to the 
paediatric age group (<18 years), 16% were between 
18–35 years, 37% were adult (35–65 years) and 24% 
were old age (>65) groups.  
Age distribution for H. influenzae: Forty-seven percent 
of patients belonged to paediatric age (<18 years), 26% of 
patients from younger age (18–35), 31% were adults (35–
65) and 19% patients were of older age (>65) group. Over 
all 64% of S. pnumoniae was isolated from male and 
36% from female, while for H. influenzae, 57% were 
from male and 43% were from female. The patient 
clinical histories for S. pneumoniae and H. influenzae are 
displayed in Table-1. One hundred and sixty-five (82%) 
of isolates collected were from out patients clinics of 
which 78 (78%) were S. pneumoniae and 87 (87%) were 
H. influenzae. Total number of isolates collected from the 
patients hospitalized for <48 hrs were 35 (18%) of which 
22 (22%) were S. pneumoniae and 13 (13%) were H. 
influenzae. Immune statuses of all patients were 
unknown. 
ANTIBIOTIC SUSCEPTIBILITY  
Disk Diffusion:  
The results of the disc susceptibility testing are given in 
Table-2. Seventy-two percent of S. pneumoniae were 
found susceptible to erythromycin and to clarithromycin 
and 97% to levofloxacin. Susceptibility of S. 
pneumoniae against ampicillin, amoxicillin, co-
amoxiclave and cefixime was tested by E test method 
only. Ninety-seven percent of H. influenza were found 
susceptible to ampicillin. All isolates of H. influenzae 
were sensitive to co-amoxiclave, cefixime and 
levofloxacin.  
Minimum Inhibitory Concentration (MIC)  
The results of MIC tests are shown in Table-3.  All S. 
pneumoniae were found susceptible to ampicillin with 
MIC range 0.016–0.25, amoxicillin 0.016–0.5, co-
amoxiclave 0.016–0.5 g/ml.  About two third isolates 
were found susceptible to erythromycin and 
clarithromycin wit MIC range of 0.032–0.5 g/ml.  
Ninety-seven percent of the isolates were susceptible to 
levofloxacin with MIC range 0.2–2 g/ml. All H. 
influenzae were found susceptible to co-amoxiclave 
with MIC range of 0.094–1 and cefixime 0.023–0.064 
g/ml. Ninety-eight percent of isolates were found 
sensitive to ampicillin with MIC range 0.019–1, 98% 
isolates were susceptible to clarithromycin with MIC 
range of 0.125–8 and 99% of the isolates were 
susceptible to levofloxacin with MIC range of 0.004–
0.016 g/ml. 
Table-1: Overall distribution of pathogens 
according to Type of Infection & Specimen Source 
 S. pneumoniae  H. influenzae  
Acute exacerbation of 
chronic bronchitis 3 1 
Acute exacerbation of 
chronic obstructive 
airways disease. - 1 
Acute otitis media 6 7 
Bacterial infection of 
Acute bronchitis 1 4 Type of
 infectio
n
 
Community acquired 
pneumoniae 90 87 
Blood culture 7 2 
Bronchial brush 5 1 
Broncheal alveolar 
Lavage. 10 2 
Endotracheal 
aspiration - 7 
Middle ear pus 
(paracentèses) 6 7 
Specime
n source
 
Sputum 72 81 
Table-2: Comparison of Disc diffusion and MICs 
(µg/ml) values of sensitive strains of S. 
pneumoniae against selected antibiotics (n=100) 
Antibiotic %S %R MIC Range (gm/ml) 
Ampicillin  -  0.016-.25 
Amoxicillin  100 - 0.016-0.5 
Co-amoxiclave 100 - 0.016-0.5 
Erythromycin 72 28 0.032-0.5 
Clarithromycin 72 28 0.032-0.5 
Levofloxacin 97 3 0.064-2 
Table-3: Comparison of Disc diffusion and MICs 
(µg/ml) values of sensitive strains of H. influenzae 
against selected antibiotics (n=100) 
Antibiotic %S %I %R 
MIC Range 
(µgm/ml) 
Ampicillin  97 - 3 0.019–1 
Co-amoxiclave  100 - - 0.094–1 
Cefixime 100 - - 0.023–0.064 
Clarithromycin 98 2 - 0.125–8 
Levofloxacin 99 - 1 0.004–0.016 
DISCUSSION AND CONCLUSIONS 
ACTIVE data was collected during the period of 2006–
2007. This study evaluated the antimicrobial 
susceptibility of community-acquired lower respiratory 
tract bacterial isolates. The results show that antibiotic 
resistance among these isolates in Pakistan is relatively 
low compared with other countries and regions 
throughout the world, as determined by recent global 
surveillance studies.6 
In this study, the macrolide class of 
antimicrobials showed poor potency against S. 
pneumoniae. Pneumococcal resistance to antimicrobials, 
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including the commonly used penicillins, macrolides 
and co-trimoxazole, has been increasing in most 
countries over the last decade, with many isolates now 
resistant to multiple antibiotics. Resistance to 
erythromycin and other macrolides among S. 
pneumoniae is increasingly been noticed in Pakistan as 
well, finding that is consistent with other countries.7 
Our results showed 28% S. pnumoniae were 
resistant to erythromycin and clarithromycin. Beta 
lacatams; ampicillin, amoxicillin, co-amoxiclave, 
cepholosporin cefixime, showed excellent MIC 
results and none of the isolate was resistant to these 
antibiotics.  Resistance to levofloxacin was detected 
in 3% of S. pnumoniae tested in this study. Similarly, 
fluoroquinolones and cephalosporins were found to 
be consistently active against H. influenzae tested in 
this study. β-lactamase producing H. influenzae is an 
emerging problem all over the world.8,9 However, our 
results suggest that β-lactamase producing strains of H. 
influenzae are less prevalent in our community as all the 
isolates were sensitive to β-lacatams, macrolides, 
cephalosporins with very low level resistance to 
ampicillin (3%). 
Although standard parameters of antimicrobial 
activity such as MIC and minimal bactericidal 
concentration are useful, they do not provide 
information about the time course or rate of kill relative 
to concentration or whether post-antibiotic effects on 
leukocytes contribute to activity. Antibiotics can be 
divided into two major groups: those that exhibit 
concentration-dependent killing and prolonged 
persistent effects and those that exhibit time-dependent 
killing and minimal-to-moderate persistent effects. With 
drugs that fall into the former group, the area under the 
concentration-time curve (AUC) and peak levels are the 
major parameters correlating with efficacy. The ratio of 
peak concentration to MIC is a measure of potency that 
also indicates the efficacy of the drug.10   
Levofloxacin demonstrates concentration-
dependent bactericidal activity most closely related to 
the pharmacodynamic parameters of the ratio of AUC to 
MIC and the ratio of peak plasma concentration (Cmax) 
to MIC. Increasing the dose of levofloxacin exploits 
these parameters by increasing peak drug 
concentrations, allowing for a shorter course of 
treatment without diminishing its therapeutic benefit.11 
The Council for Appropriate and Rational Antibiotic 
Therapy (CARAT) criteria, as well as the World Health 
Organization recommendations, emphasize the 
importance of choosing the best possible drug for the 
optimal duration to prevent the further emergence of 
resistant bacterial strains.12 Other potential benefits of a 
short-course, higher-dose therapy include less total drug 
exposure, avoidance of adverse effects, enhanced patient 
and healthcare worker convenience, adherence, and 
improved cost-effectiveness.13 
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